Old drug, new hope: ibrutinib combo tackles childhood brain tumors
NCT ID NCT05106296
First seen Jan 11, 2026 · Last updated Apr 29, 2026 · Updated 16 times
Summary
This early-phase trial tests whether adding the drug ibrutinib to a chemotherapy and immunotherapy combination can help children and young adults (ages 6–25) with brain cancers that have come back or not responded to standard treatment. The study aims to find the safest dose of ibrutinib and check for early signs of tumor shrinkage. Participants receive either one of two chemotherapy backbones alongside ibrutinib and an experimental immune-boosting drug called indoximod.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Augusta University, Georgia Cancer Center
RECRUITINGAugusta, Georgia, 30912, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.